A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
Part of paid clinical trials in Huntsville, Alabama.
- Sponsor
- Beijing Inno Medicine Co., Ltd.
- Study ID
- NCT07521007
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Atherosclerosis
- Coronary Artery Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- YN001/Placebo 40mg — DRUGDose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.
- YN001/Placebo 20mg — DRUGYN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.
- YN001/Placebo 0mg — DRUGYN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.
Study Details
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
Key Dates
- First listed
- Apr 9, 2026
- Start date
- Jul 31, 2026
- Status verified
- Sep 2026
- Primary completion
- Jul 31, 2027
- Completion
- Mar 31, 2029
Study Design
- Enrollment
- 456 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dose 1 YN001/Placebo 40mgDose 1 YN001/Placobo 40mg will be administrated intravenously weekly
- Experimental: Dose 2 YN001/Placebo 20mgDose 2 YN001/Placebo 20mg will be administrated intravenously weekly
- Placebo Comparator: Dose 3 YN001/Placebo 0mgDose 3 YN001/Placebo 0mg will be administrated intravenously weekly
Primary Outcome Measure
Relative change from baseline in coronary NCPV at Week 13 [ Time Frame: Baseline to Week 13 ]
Central Contacts
- Jingmei Zhang, Master0086 010 82599080
- Kaiqi Zong, Master0086 010 82599080
Locations (22)
Find similar trials in Huntsville, AL
By research site
Heart Center Research, LLC· Huntsville, ALThrive Clinical Research Group, LLC· Covina, CAClinical Trials Research· Lincoln, CAUniversity of California Irvine Medical Center - Cardiovascular Center· Los Alamitos, CAStanford Health Care General Cardiology· Stanford, CALundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center· Torrance, CA
Related Studies
- Study of the Effect of Innate on the Inflammatory Response to EndotoxinRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Research Triangle Park, North Carolina
- Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem CellsEnrolling By Invitation · Scripps Translational Science Institute · La Jolla, California
- Product Surveillance RegistryRecruiting · Medtronic · Birmingham, Alabama
- Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)PHASE2 · Not Yet Recruiting · Cell>Point LLC · Oklahoma City, Oklahoma